Elidel

/ Dexcel

– The patient or care giver should apply a thin layer of Elidel® (pimecrolimus) Cream 1% to the affected skin twice daily. The patient or caregiver should stop using when signs and symptoms (e.g., itch, rash and redness) resolve and should be instructed on what actions to take if symptoms recur.
– If signs and symptoms persist and beyond 6 weeks, patients should be re-examined by their health care provider to confirm the diagnosis of atopic dermatitis.
– Continuous long-term use of Elidel Cream should be avoided, and application
should be limited to areas of involvement with atopic dermatitis.
The safety of Elidel Cream under occlusion, which may promote systemic exposure, has not been evaluated. Elidel Cream should not be used with occlusive dressings.

Short term treatment of signs and symptoms of atopic dermatitis (eczema) and intermittent long term treatment to prevent progression of flares in patients 3 months of age and above, in patients in whom the use of conventional topical corticosteroid therapy is deemed inadvisable because of the potential risks, or in patients who are not adequately responsive to or intolerant to conventional topical corticosteroid therapy.

Hypersensitivity to any of the components of the cream. Should not be applied to the breast during breastfeeding.

In the absence of compatibility studies, this medicdbinal product must not be mixed with other topical medicdbinal products.